Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 130, Issue 12, Pages 6214-6217Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI143361
Keywords
-
Categories
Funding
- Department of Defense (DoD) [W81XWH-16-1-0510]
- DoD [W81XWH-16-1-0509]
Ask authors/readers for more resources
COVID-19 spans a wide range of symptoms, sometimes with profound immune system involvement. How immune cell subsets change during the disease course and with disease severity needs further study. While myeloid cells have been shown to initiate and maintain responses to pneumonia and lung inflammation, often playing a role in resolution, their involvement with COVID-19 remains unknown. In this issue of the JCI, Sanchez-Cerrillo and Landete et al. investigated DCs and monocytes from blood and bronchial secretions of patients with varying COVID-19 severity and with healthy controls. The authors conclude that circulating monocytes and DCs migrate from the blood into the inflamed lungs. While sampling differences in sex, collection timing, bacteria/fungal infection, and corticosteroid treatment limit interpretation, we believe that reprogramming monocyte or macrophages by targeting immunometabolism, epigenetics, or the cytokine milieu holds promise in resolving lung inflammation associated with COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available